Avasimibe (0, 0.25, 5, 10, 20, 40 and 80 µM; for 1, 2, and 3 days) reduces proliferation in the prostate cancer (PCa) cells.
Avasimibe (10 and 20 µM; 48 h) reduces the expression of β-catenin, Vimentin, N-cadherin, Snail and MMP9, which are tightly associated with epithelial-mesenchymal transition (EMT).
Avasimibe (10 and 20 µM) trigger cell cycle arrest via the E2F-1 signalling pathway in prostate cancer. Avasimibe induces G1 phase cell cycle arrest of PCa cells.
Avasimibe (10 and 20 µM) inhibits the metastasis of PCa cells.
Cell Viability Assay
| Cell Line: |
PCa cells (PC-3 and DU 145) |
| Concentration: |
0, 0.25, 5, 10, 20, 40 and 80 µM |
| Incubation Time: |
1, 2, and 3 days |
| Result: |
Dose dependently inhibited PC-3 and DU 145 cell viability. |
Western Blot Analysis
| Cell Line: |
PCa cells (PC-3 and DU 145) |
| Concentration: |
10 and 20 µM |
| Incubation Time: |
48 hours |
| Result: |
Reduced protein levels of EMT-related proteins (β-catenin, Vimentin, N-cadherin, Snail, MMP9 and E-cadherin). |
Cell Cycle Analysis
| Cell Line: |
PCa cells (PC-3 and DU 145) |
| Concentration: |
10 and 20 µM |
| Incubation Time: |
48 hours |
| Result: |
Induced G1 phase cycle arrest and altered the G1 phase-related protein levels in PCa cells. |